Atorvastatin attenuates homocysteine-induced apoptosis in human umbilical vein endothelial cells via inhibiting NADPH oxidase-related oxidative stress-triggered p38MAPK signaling

Acta Pharmacologica Sinica

Volumn 30, Issue 10, 2009, Pages 1392-1398

  Bao, Xiao Mei ^a   Wu, Chun Fang ^a   Lu, Guo Ping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Atorvastatin; Homocysteine; Human umbilical vein endothelial cells; NADPH oxidase; P38MAPK; Reactive oxygen species

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCYSTEINE; ATORVASTATIN; DIPHENYLIODONIUM SALT; HOMOCYSTEINE; LIPOCORTIN 5; LUCIGENIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROPIDIUM IODIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

APOPTOSIS; ARTICLE; CELL CULTURE; CHEMOLUMINESCENCE; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OXIDATIVE STRESS; UMBILICAL VEIN; WESTERN BLOTTING;

APOPTOSIS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HEPTANOIC ACIDS; HOMOCYSTEINE; HUMANS; IMIDAZOLES; NADPH OXIDASE; ONIUM COMPOUNDS; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRIDINES; PYRROLES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TIME FACTORS; UMBILICAL VEINS;

EID: 70350641535     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.135     Document Type: Article

References (30)

1. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-1155
2. Audelin MC, Genest J Jr. Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 2001; 159: 497-511.
3. Bautista LE, Arenas IA, Peñuela A , Martínez LX. Total plasma homocysteine level and risk of cardiovascular disease: a metaanalysis of prospective cohort studies. J Clin Epidemiol 2002; 55: 882-887
4. Weiss N, Keller C, Hoffmann U, Loscalzo J. Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med 2002; 7: 227-239
5. Vignini A, Nanetti L, Bacchetti T, Ferretti G, Curatola G, Mazzanti L. Modification induced by homocysteine and low-density lipoprotein on human aortic endothelial cells: an in vitro study. J Clin Endocrinol Metab 2004; 89: 4558-4561
6. Grover-Páez F, Zavalza-Gómez AB. Endothelial dysfunction and cardiovascula risk factors. Diabetes Res Clin Pract 2009; 84: 1-10.
7. Galle J, Schneider R, Heinloth A, Wanner C, Galle PR, Conzelmann E, et al. Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress. Kidney Int 1999; 55: 1450-1461
8. Xu Z, Lu G, Wu F. Simvastatin suppresses homocysteine-induced apoptosis in endothelial cells: roles of caspase-3, cIAP-1 and cIAP-2. Hypertens Res 2009; 32: 375-380
9. Lee SJ, Kim KM, Namkoong S, Kim CK, Kang YC, Lee H, et al. Nitric oxide inhibition of homocysteine-induced human endothelial cell apoptosis by down-regulation of p53-dependent Noxa expression through the formation of S-nitrosohomocysteine. J Biol Chem 2005; 280: 5781-5788
10. Au-Yeung KK, Woo CW, Sung FL, Yip JC, Siow YL, O K. Hyperhomocysteinemia activates nuclear factor-kappaB in endothelial cells via oxidative stress. Circ Res 2004; 94: 28-36.
11. Alvarez-Maqueda M, El Bekay R, Monteseirín J, Alba G, Chacón P, Vega A, et al. Homocysteine enhances superoxide anion release and NADPH oxidase assembly by human neutrophils. Effects on MAPK activation and neutrophil migration. Atherosclerosis 2004; 172: 229-238
12. Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. Curr Drug Metab 2005; 6: 27-36.
13. Ungvari Z, Csiszar A, Edwards JG, Kaminski PM, Wolin MS, Kaley G, et al. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 2003; 23: 418-424
14. Carluccio MA, Ancora MA, Massaro M, Carluccio M, Scoditti E, Distante A, et al. Homocysteine induces VCAM-1 gene expression through NF-kappaB and NAD(P)H oxidase activation: protective role of Mediterranean diet polyphenolic antioxidants. Am J Physiol Heart Circ Physiol 2007; 293: H2344-54.
15. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001; 49: 281-287
16. Rubba P. Effects of atorvastatin on the different phases of atherogenesis. Drugs 2007; 67: 17-27.
17. Wassmann S, Laufs U, Müller K, Konkol C, Ahlbory K, Bäumer AT, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300-305
18. Goettsch C, Goettsch W, Muller G. Nox4 overexpression activates reactive oxygen species and p38 MAPK in human endothelial cells. Biochem Biophys Res Commun 2009; 380: 355-360
19. El-Remessy AB, Tang Y, Zhu G, Matragoon S, Khalifa Y, Liu EK, et al. Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation. Mol Vis 2008; 14: 2190-2203
20. Uruno A, Sugawara A, Kudo M, Satoh F, Saito A, Ito S. Stimulatory effects of low-dose 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin on hepatocyte growth factor-induced angiogenesis: involvement of p38 mitogen-activated protein kinase. Hypertens Res 2008; 31: 2085-96.
21. ten Freyhaus H, Huntgeburth M, Wingler K, Schnitker J, Bäumer AT, Vantler M, et al. Novel Nox inhibitor VAS2870 attenuates PDGFdependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc Res 2006; 71: 331-341
22. Li L, Zhu DL, Shen WL, Gao PJ. Increased migration of vascular adventitial fibroblasts from spontaneously hypertensive rats. Hypertens Res 2006; 29: 95-103.
23. Bessede G, Miguet C, Gambert P, Neel D, Lizard G. Efficiency of homocysteine plus copper in inducing apoptosis is inversely proportional to gamma-glutamyl transpeptidase activity. FASEB J 2001; 15: 1927-1940
24. Di Simone N, Maggiano N, Caliandro D, Riccardi P, Evangelista A, Carducci B, et al. Homocysteine induces trophoblasts cell death with apoptotic features. Biol Reprod 2003; 69: 1129-1134
25. Kerkeni M, Tnani M, Chuniaud L, Miled A, Maaroufi K, Trivin F. Compara tive study on in vitro effects of homocysteine thiolactone and homocysteine on HUVEC cells: Evidence for a stronger proapoptotic and proinflammative homocysteine thiolactone. Mol Cell Biochem 2006; 291: 119-126
26. Huang RF, Huang SM, Lin BS, Wei JS, Liu TZ. Homocysteine thiolactone induces apoptotic DNA damage mediated by increased intracellular hydrogen peroxide and caspase-3 activation in HL-60 cells. Life Sci 2001; 68: 2799-2811
27. Abid MR, Spokes KC, Shih SC, Aird WC. NADPH oxidase activity selectively modulates vascular endothelial growth factor signaling pathways. J Biol Chem 2007; 282: 35373-35385
28. Kuroda J, Nakagawa K, Yamasaki T, Nakamura K, Takeya R, Kuribayashi F, et al. The superoxide-producing NAD(P)H oxidase Nox4 in the nucleus of human vascular endothelial cells. Genes Cells 2005; 10: 1139-1151
29. Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 1996; 60: 687-695
30. Outinen PA, Sood SK, Pfeifer SI, Pamidi S, Podor TJ, Li J, et al. Homocysteine induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cell. Blood 1999; 94: 959-967